NantKwest and its sister firm ImmunityBio have partnered for the development of potential vaccines and therapeutics against Covid-19.
Currently, the companies are in discussions with the US Food and Drug Administration (FDA). The partnership combines NantKwest’s off-the-shelf, cell-based therapeutics expertise with ImmunityBio’s vaccine development and natural killer cell activation capabilities.
NantKwest and ImmunityBio will leverage their respective resources for the design and development of both vaccines and drugs.
NantKwest and ImmunityBio chairman and CEO Patrick Soon-Shiong said: “We’re in a race against time, but I am confident that, as a result of the incredible hard work the NantKwest, ImmunityBio, and the global scientific